Background
==========

Obstructive sleep apnea (OSA) is a common sleep-related breathing disorder characterized by intermittent hypoxia (IH), which leads to hypoxemia, hypercapnia, sleep fragmentation, increased respiratory effort, and increased sympathetic activity. OSA commonly affects middle-aged adults, affecting 4% of men and 2% of women \[[@b1-medscimonit-22-908],[@b2-medscimonit-22-908]\]. However, the prevalence of sleep-disordered breathing in men and women who do not have daytime somnolence is approximately 24% and10%, respectively. Moreover, in obese and elderly populations, this value increases to 60% \[[@b3-medscimonit-22-908]\].

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide, affecting 30% of the general adult population and 60--70% of diabetic and obese patients \[[@b4-medscimonit-22-908]\]. NAFLD is a significant public health problem; in a 5-year population-based follow-up, the presence of NAFLD increased overall healthcare costs by 26%, after controlling for comorbidities \[[@b5-medscimonit-22-908]\].

Obstructive sleep apnea syndrome has been associated with the features of metabolic syndrome, including obesity \[[@b6-medscimonit-22-908]\], hypertension \[[@b7-medscimonit-22-908]\], dyslipidemia \[[@b8-medscimonit-22-908]\], and insulin resistance \[[@b9-medscimonit-22-908]\], some of which are thought to contribute to the pathogenesis of NAFLD \[[@b10-medscimonit-22-908]\]. Therefore, this study evaluated the relationship between OSA and fatty liver.

Material and Methods
====================

Subjects
--------

This study was approved by the local ethics committee in accordance with the Helsinki Declaration. Written informed consent was received from the OSA syndrome subjects and control subjects before enrollment in the study. This study enrolled 176 subjects who underwent polysomnography (PSG) for suspected OSA between January 2013 and April 2015 at our sleep center. Exclusion criteria were: severe disease of the circulatory, respiratory, central nervous, or digestive systems; alcohol intake \>20 g/d for males and \>10 g/d for females; regular use of hepatotoxic drugs; evidence of hepatitis; use of hyperlipidemia drugs; and subjects with diabetes mellitus. Blood tests and ultrasound imaging of the subjects were performed the morning of the PSG. The OSA subjects had an apnea-hypopnea index (AHI) ≥5, while the subjects with an AHI \<5 were considered contols. The OSA subjects were subdivided into mild, moderate, and severe OSA groups based on the American Academy of Sleep Medicine criteria, with an AHI of 5--14, 15--29, and ≥30 events/h, respectively.

Demographic data and laboratory tests
-------------------------------------

We collected demographic data, including a history of hypertension, diabetes mellitus, and medications. The physician who collected these data was blinded to the blood and PSG test results. The height and weight of all subjects were measured by the same person and with the same equipment using a calibrated hospital scale. Oher baseline characteristics recorded in all patients included age, sex, and body mass index (BMI), which was calculated by dividing body weight by height squared (kg/m^2^).

Fasting blood samples were drawn into heparinized tubes, and centrifuged at 3000 rpm for 10 min to separate the plasma. The samples were analyzed within 2 h. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), total serum cholesterol and triglycerides, low-density lipoprotein, high-density lipoprotein (HDL), platelet count, and hemoglobin level were measured using standard techniques.

PSG
---

Overnight PSG was performed using a 16-channel Embla device (Medcare, Reykjavik, Iceland) under continuous monitoring by a sleep technician. The system consists of 4 electroencephalogram channels (with electrodes placed at C4-A1, C3-A2, O2-A1, and O1-A2), 2 electrooculogram channels, and a submental electromyogram (EMG); it monitors nasal airflow using a nasal pressure cannula, thoracic and abdominal movements, pulse oximeter oxygen saturation, tibial EMG, body position, electrocardiogram readings, and tracheal sound. Sleep-disordered breathing events were scored manually by the same examiner according to the 2012 American Academy of Sleep Medicine criteria. Apnea was defined as complete cessation of airflow lasting more than 10 s. Hypopnea was defined as a reduction in airflow \>30% lasting more than 10 s accompanied by ≥4% desaturation or arousal. The average number of episodes of apnea and hypopnea per hour of sleep was measured as the AHI. Sleep stages were scored using standard criteria with 30-s epochs, and were reviewed and verified by a certified sleep physician. The pulmonologist who evaluated the PSG was blind to the ultrasonography results. The duration of desaturation, lowest saturation, mean saturation, average desaturation, and other polysomnography parameters were recorded.

Ultrasound imaging
------------------

Using B-mode sonography, the presence or absence and severity of fatty infiltration were graded on a scale from 0 to 3, indicating absent, mild, moderate, and severe hepatosteatosis, respectively, as reported by Mihmanli et al. \[[@b10-medscimonit-22-908]\]. These correspond to increasing degrees of hepatic echogenicity with poorer visualization of the intrahepatic vessels and diaphragm. Grade 0 (control) subjects had normal liver echogenicity. Grade 1 subjects had a minimal diffuse increase in hepatic echogenicity, with normal visualization of the diaphragm and walls of the intrahepatic vessels. Grade 2 subjects had a moderate diffuse increase in hepatic echogenicity, with slightly impaired visualization of the hepatic veins and diaphragm. Grade 3 subjects had a marked increase in echogenicity with poor penetration of the posterior portion of the right lobe of the liver, and poor or no visualization of the hepatic veins and diaphragm. The radiologist who evaluated the ultrasound imaging was blind to the PSG results.

Statistical analyses
--------------------

Statistical analyses were performed using SPSS 21. Continuous data are expressed as the means ± standard deviation (SD). Statistical comparisons were performed using one-way analysis of variance. We compared AHI, hepatosteatosis grade, age, lowest saturation, BMI, duration under 90% saturation, average saturation, AST and ALT levels, lipid profile, hemoglobin, and platelet count between the OSA subjects and controls. Logistic regression analysis of the factors that affected hepatic steatosis independently was performed. Results were considered statistically significant when the *p*-value was ≤0.05.

Results
=======

The study enrolled 176 patients, including 130 males. The mean age was not significantly different in the non-OSA and mild, moderate, and severe OSA groups. The sex distribution was not significantly different between the control and OSA groups, but the percentage of males was higher than that of females in all groups. [Table 1](#t1-medscimonit-22-908){ref-type="table"} summarizes the demographic parameters, clinical characteristics, and PSG parameters. The simple snoring and mild, moderate, and severe OSA groups included 18/42 (42.86%), 33/52 (63.5%), 27/34 (79.4%), and 28/48 (79.2%) subjects with hepatosteatosis, respectively (*p*=0.001).

The BMI, AHI, hepatosteatosis grade, duration of desaturation, lowest desaturation, mean saturation, average desaturation, and AST and ALT levels differed significantly among the groups. There were no differences in the other parameters. BMI differed significantly between the simple snoring and the moderate and severe OSA groups (*p*=0.002 for simple snoring *vs.* moderate OSA groups, *p*=0.002 for simple snoring *vs*. severe OSA groups). There were no differences in BMI between the moderate OSA and the simple snoring and mild and severe OSA groups.

Parameters that differed between the groups were identified using one-way analysis of variance and Bonferroni correction. The significant results are given in [Table 2](#t2-medscimonit-22-908){ref-type="table"}. There were significant differences in hepatosteatosis and hepatosteatosis grade between the simple snoring and the moderate and severe OSA groups. In addition, AHI, BMI, hepatosteatosis grade, lowest desaturation, mean desaturation, AST, ALT, cholesterol, HDL, and triglyceride levels differed significantly when the subjects were separated into hepatosteatosis and non-hepatosteatosis groups (*p*-values 0.004, \<0.001, \<0.001, 0.007, \<0.001, 0.005, \<0.001, 0.045, 0.043, and 0.029, respectively)

Using logistic regression, BMI and average desaturation were independently and significantly related to hepatic steatosis (*p*=0.014, r=1.1126, and *p=*0.008 and r=2.327, respectively) ([Table 3](#t3-medscimonit-22-908){ref-type="table"}). Receiver operating characteristic curve analysis was performed to examine the average desaturation and hepatosteatosis. The cut-off value was 4.85% for average desaturation on hepatosteatosis (sensitivity was 80% and specificity was 57%) ([Figure 1](#f1-medscimonit-22-908){ref-type="fig"}).

Discussion
==========

Our data indicate that BMI and the average desaturation contribute to non-alcoholic fatty liver in subjects with OSA. The BMI and average desaturation (%) increased progressively from simple snoring to severe OSA; hepatosteatosis and hepatosteatosis grade also increased significantly. The average desaturation was a risk factor for hepatic steatosis after adjusting for BMI.

Obstructive sleep apnea syndrome (OSAS) is characterized by episodes of chronic intermittent hypoxia and sleep fragmentation, which increase sympathetic activity and promote oxidative stress, proinflammatory cytokine production, platelet aggregation, endothelial dysfunction, and metabolic dysregulation \[[@b11-medscimonit-22-908]\]. Collectively, these mechanisms provide the pathophysiological basis for increased risk of fatty liver observed in these patients.

Recently, OSAS has been associated with non-alcoholic fatty liver disease (NAFLD) \[[@b12-medscimonit-22-908]\]. NAFLD is the most common chronic liver disease worldwide and about 30% of the general adult population and 60--70% of diabetic and obese patients have NAFLD \[[@b13-medscimonit-22-908]\]. The liver damage of NAFLD ranges from simple steatosis to non-alcoholic steatohepatitis (NASH).

Chronic intermittent hypoxia (CIH) is a key feature in the pathophysiology of OSAS. The mechanism is probably similar to that of ischemia-reperfusion injury. In OSAS patients, some oxidative stress markers are augmented and can increase inflammation, endothelial dysfunction, and the development of atherosclerosis \[[@b14-medscimonit-22-908]\].

Savransky et al. showed that CIH induces hyperglycemia and hepatic lipid peroxidation and enhances the activity of nuclear factor kappa B (NF-κB), a master regulator of the inflammatory response. Liver histology is characterized by swelling and a significant increase in the accumulation of glycogen in hepatocytes. Therefore, CIH may independently lead to mild liver injury in the absence of factors that induce obesity \[[@b15-medscimonit-22-908]\].

Hypoxia modulates target gene expression through a number of transcription factors, including hypoxia-inducible factors (HIFs). HIFs are heterodimers consisting of α and β subunits. HIF-α subunits are produced constitutively in normoxic cells and are immediately degraded via hydroxylation by 3 prolyl-hydroxylases. In OSAS patients, CIH can increase active HIF levels. In an animal model, CIH led to hypercholesterolemia and hepatic lipid peroxidation, in the absence of obesity \[[@b12-medscimonit-22-908]\].

Recent experimental evidence has connected OSAS to the pathogenesis and progression of NAFLD, another obesity-related disorder, which is associated with increased cardio-metabolic and liver-related risk \[[@b16-medscimonit-22-908]\]. In cellular and animal models, CIH promoted hepatic triglyceride accumulation, necroinflammation, and fibrosis via the activation of several cellular pathways, including hypoxia-inducible factors, NF-κB, and the unfolded protein response \[[@b17-medscimonit-22-908]\]. Furthermore, epidemiological studies have documented an association of OSAS with increased prevalence and severity of NAFLD, and a few trials have documented the benefits of OSAS treatment on transaminase elevation and radiological steatosis \[[@b18-medscimonit-22-908]--[@b20-medscimonit-22-908]\].

Turkay et al. examined liver functions tests, liver ultrasonography, and markers of OSA severity (AHI, oxygen desaturation index, minimum oxygen saturation, and percentage of duration of desaturation) and concluded that as the severity of NAFLD increased from mild to severe, the mean AHI and oxygen desaturation index also increased significantly \[[@b21-medscimonit-22-908]\]. Their study differed from ours in that they investigated the presence of OSA in subjects with or without fatty liver.

Few studies have focused on hepatosteatosis in subjects with OSA. We found that the BMI, AHI, hepatosteatosis grade, duration of desaturation, lowest desaturation, mean saturation, average desaturation, and AST and ALT levels differed significantly among the 4 groups. In addition, AHI, BMI, hepatosteatosis grade, lowest desaturation, mean desaturation, AST, ALT, cholesterol, HDL, and triglyceride levels differed significantly in the subjects with hepatosteatosis. However, only BMI and average desaturation had independent effects on hepatosteatosis in subjects with OSA. This study cannot explain why the lowest saturation, mean saturation, and duration of desaturation had no effects on hepatosteatosis. Further studies should examine this topic.

Conclusions
===========

Average desaturation and BMI were the parameters with the greatest independent effects on hepatosteatosis in the subjects with OSA. Hepatosteatosis in individuals with OSA should be monitored carefully with ultrasonography. OSA patients should be encouraged to use a continuous positive airway pressure (CPAP) device and lose weight to prevent development of fatty liver.
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###### 

Demographic, clinical characteristics and polysomnographic parameters in subjects with OSA groups and control (simple snoring) group.

                                   Groups           p value                                         
  -------------------------------- ---------------- --------------- --------------- --------------- ---------
  Subjects (n)                     42               52              34              48              
  Sex (f/m)                        11/31            14/38           9/25            12/36           0.997
  Age                              45.09±10.08      42.87±9.63      47.59±10.79     46.96±10.04     0.112
  AHI (event/h)                    2.9±3.4          9.5±3.8         20.2±5.3        55.9±23         \<0.001
  BMI (kg/m^2^)                    28.35±4.71       30.11±6.17      34.14±7.7       32.7±6.23       \<0.001
  Hepatosteatosis (n/%)            18/42 (42.86%)   33/52 (63.5%)   27/34 (79.4%)   28/48 (79.2%)   0.001
  Hepatosteatosis grade            .74±0.96         1.19±1.12       1.65±1.12       1.54±1.03       0.001
  Duration of desaturation (min)   9.36±24.71       34.11±59.1      56.86±52.82     47.54±37.12     \<0.001
  Lowest desaturation (%)          85.88±7.01       82.67±4.91      77.21±8.96      69.06±12.46     \<0.001
  Avarage saturation (%)           91.98±2.26       91.12±2.14      89.06±4.44      85.41±7.3       \<0.001
  Avarage desaturation (%)         5.72±7.33        5.1±0.59        5.84±1.05       8.27±3.78       0.001
  AST (UI/L)                       24.12±9.60       22.29±9.07      24.94±7.47      27.65±10.89     0.045
  ALT (UI/L)                       26.14±12.63      27.16±11.71     30.71±16.47     37.73±23.04     0.004
  Cholesterol (mg/dL)              192.12±44.96     195.54±32.68    183.0±36.53     193.34±38.07    0.512
  LDL (mg/dL)                      114.67±38.89     120.84±31.21    111.18±27.43    117.40±30.73    0.585
  HDL (mg/dL)                      38.40±7.99       40.2±10.85      40.73±10.34     37.43±7.22      0.318
  Triglycerides (mg/dL)            197.60±141.92    177.06±94.44    166.22±102.67   198.63±98.03    0.488
  Hb (g/dL)                        15.25±1.34       14.95±1.8       15.05±1.37      15.56±1.67      0.258

###### 

Bonferroni test results for studied parameters.

  Multiple comparisons                                                             
  -------------------------- ---------------- -------------- ----------- --------- ------
  Hepatosteatoz              Simple snoring   Moderate OSA   −.36555     .10528    .004
  Severe OSA                 −.36310          .09642         .001                  
  Hepatosteatosis grade      Simple snoring   Moderate OSA   −.90896     .24493    .002
  Severe OSA                 −.80357          .22432         .003                  
  Duration of desaturation   Simple snoring   Mild OSA       −24.75175   9.60799   .065
  Moderate OSA               −47.50567        10.62465       .000                  
  Severe OSA                 −38.18220        9.78849        .001                  
  Lowest desaturation        Simple snoring   Moderate OSA   8.67217     2.03756   .000
  Severe OSA                 16.81555         1.86807        .000                  
  Mild OSA                   Severe OSA       13.60417       1.76654     .000      
  Moderate OSA               Mild OSA         −5.46078       1.94489     .033      
  Severe OSA                 8.14338          1.96905        .000                  
  Avarage saturation         Simple snoring   Severe OSA     6.56311     .97729    .000
  Mild OSA                   Severe OSA       5.70711        .92417      .000      
  Moderate OSA               Simple snoring   −2.91679       1.06595     .041      
  Severe OSA                 3.64632          1.03012        .003                  
  Avarage desaturation       Simple snoring   Severe OSA     −2.54228    .87949    .026
  Mild OSA                   Severe OSA       −3.16667       .83987      .001      
  Moderate OSA               Severe OSA       −2.42255       .92703      .059      
  ALT                        Simple snoring   Severe OSA     −11.58631   3.51969   .007
  Mild OSA                   Severe OSA       −10.56917      3.36617     .012      

###### 

Logistic regresyon analyse results basing on hepatosteatosis.

                             B         S.E.    Wald    df   Sig.   Exp(B)   95.0% C.I. for EXP(B)   
  -------------------------- --------- ------- ------- ---- ------ -------- ----------------------- -------
  Sex                        −.765     .649    1.392   1    .238   .465     .130                    1.659
  Age                        −.012     .024    .264    1    .607   .988     .942                    1.035
  AHI                        −.024     .017    2.044   1    .153   .976     .944                    1.009
  BMI                        .119      .048    6.016   1    .014   1.126    1.024                   1.238
  Duration of Desaturation   .004      .005    .434    1    .510   1.004    .993                    1.014
  LowestDesaturation         .020      .045    .196    1    .658   1.020    .934                    1.114
  Mean Saturation            .034      .089    .146    1    .703   1.034    .869                    1.231
  Avarage Desaturation       .845      .321    6.941   1    .008   2.327    1.241                   4.363
  Cholesterol                .018      .048    .148    1    .701   1.019    .927                    1.119
  LDL                        −.006     .049    .014    1    .907   .994     .904                    1.094
  HDL                        −.054     .050    1.191   1    .275   .947     .859                    1.044
  Triglycerides              −.004     .010    .150    1    .699   .996     .977                    1.015
  Hb                         .064      .187    .117    1    .732   1.066    .739                    1.539
  Constant                   −14.691   8.003   3.370   1    .066   .000                             
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